High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: Baseline data from the US PrEP demonstration project

Journal of Acquired Immune Deficiency Syndromes

Volumn 68, Issue 4, 2015, Pages 439-448

  Cohen, Stephanie E ^a   Vittinghoff, Eric ^a   Bacon, Oliver ^a   Doblecki Lewis, Susanne ^b   Postle, Brian S ^c   Feaster, Daniel J ^b   Matheson, Tim ^a   Trainor, Nikole ^a   Blue, Robert W ^a   Estrada, Yannine ^b   Coleman, Megan E ^d   Elion, Richard ^d   Castro, Jose G ^b   Chege, Wairimu ^e   Philip, Susan S ^a   Buchbinder, Susan ^a   Kolber, Michael A ^b   Liu, Albert Y ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c DF/Net Research   (United States)

^d WhitmanWalker GMHW Clinic   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

HIV prevention; implementation; men who have sex with men; preexposure prophylaxis; sexually transmitted diseases

Indexed keywords

EMTRICITABINE; TENOFOVIR; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DEOXYCYTIDINE; PHOSPHONIC ACID DERIVATIVE;

ADULT; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; DRUG USE; FEMALE; FOLLOW UP; GONORRHEA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; OPEN STUDY; PATIENT PARTICIPATION; PATIENT REFERRAL; PERCEPTION; PRE-EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCREENING; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; SYPHILIS; TRANSGENDER; ADOLESCENT; ANALOGS AND DERIVATIVES; CHEMOPROPHYLAXIS; DISEASE TRANSMISSION; HIV INFECTIONS; MALE HOMOSEXUALITY; PATIENT ATTITUDE; PREVENTION AND CONTROL; PROCEDURES; TRANSMISSION; UNITED STATES; UTILIZATION; YOUNG ADULT;

ADENINE; ADOLESCENT; ADULT; ANTI-HIV AGENTS; CHEMOPREVENTION; COHORT STUDIES; DEOXYCYTIDINE; DISEASE TRANSMISSION, INFECTIOUS; EMTRICITABINE; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; LONGITUDINAL STUDIES; MALE; ORGANOPHOSPHONATES; PATIENT ACCEPTANCE OF HEALTH CARE; PRE-EXPOSURE PROPHYLAXIS; PROSPECTIVE STUDIES; TENOFOVIR; UNITED STATES; YOUNG ADULT;

EID: 84924517617     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000479     Document Type: Conference Paper

References (48)

1. Centers for Disease Control and Prevention. Estimated HIV incidence in the United States, 2007-2010. HIV Surveilance Rep. 2012;17:4-15
2. Prejean J, Song R, Hernandez A, et al. Estimated HIV incidence in the United States, 2006-2009. PLoS One. 2011;6:e17502
3. Clements-Nolle K, Marx R, Guzman R, et al. HIV prevalence, risk behaviors, health care use, and mental health status of transgender persons: implications for public health intervention. Am J Public Health. 2001;91:915-921
4. Edwards JW, Fisher DG, Reynolds GL. Male-To-female transgender and transsexual clients of HIV service programs in Los Angeles County, California. Am J Public Health. 2007;97:1030-1033
5. Nemoto T, Operario D, Keatley J, et al. HIV risk behaviors among maleto-female transgender persons of color in San Francisco. Am J Public Health. 2004;94:1193-1199
6. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363:2587-2599
7. Anderson PL, Glidden DV, Liu A, et al. Emtricitabine-Tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012;4:151ra125
8. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367: 399-410
9. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367:423-434
10. FDA Approves First Drug for Reducing the Risk of Sexually Acquired HIV Infection: US Food and Drug Administration, 2012. Available at: http://www.fda.gov/newsevents/newsroom/pressannouncements/.ucm312210.htm. Accessed February 1, 2014
11. Holmes D. FDA paves the way for pre-exposure HIV prophylaxis. Lancet. 2012;380:325
12. Pre-Exposure Prophylaxis for the Prevention of HIV Infection in the United States-2014, A Clinical Practice Guideline: United states public health service, 2014. Available at: http://www.cdc.gov/hiv/pdf/.PrEPguidelines2014.pdf. Accessed June 15, 2014
13. Desai K, Sansom SL, Ackers ML, et al. Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness. AIDS. 2008;22:1829-1839
14. Paltiel AD, Freedberg KA, Scott CA, et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis. 2009;48:806-815
15. Juusola JL, Brandeau ML, Owens DK, et al. The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. Ann Intern Med. 2012;156:541-550
16. Silva A, Mera R, Ng L, et al. Characteristics of Truvada for pre-exposure prophylaxis: users in the US. Presented at: HIV Drug Therapy in the Americas Conference; 2014; Rio de Janeiro, Brazil
17. Saberi P, Gamarel KE, Neilands TB, et al. Ambiguity, ambivalence, and apprehensions of taking HIV-1 pre-exposure prophylaxis among male couples in San Francisco: a mixed methods study. PLoS One. 2012;7:e50061
18. Fuchs J, Sobieszczyk ME, Madenwald T, et al. Intentions to use preexposure prophylaxis among current phase 2B preventative HIV-1 vaccine efficacy trial participants. J Acquir Immune Defic Syndr. 2013; 63:259-262
19. Krakower DS, Mimiaga MJ, Rosenberger JG, et al Of pre-exposure prophylaxis among men who have sex with men using an Internet social Networking site. PLoS One. 2012;7:e33119
20. Horberg M, Raymond B. Financial policy issues for HIV pre-exposure prophylaxis: cost and access to insurance. Am J Prev Med. 2013;44(1 suppl 2):S125-S128
21. Tellalian D, Maznavi K, Bredeek UF, et al. Pre-exposure prophylaxis (PrEP) for HIV infection: results of a survey of HIV healthcare providers evaluating their knowledge, attitudes, and prescribing practices. AIDS Patient Care and STDS. 2013;27:553-559
22. White JM, Mimiaga MJ, Krakower DS, et al. Evolution of Massachusetts physician attitudes, knowledge, and experience regarding the use of antiretrovirals for HIV prevention. AIDS Patient Care STDS. 2012;26: 395-405
23. Arnold EA, Hazelton P, Lane T, et al. A qualitative study of provider thoughts on implementing pre-exposure prophylaxis (PrEP) in clinical settings to prevent HIV infection. PLoS One. 2012;7:e40603
24. Tripathi A, Ogbuanu C, Monger M, et al. Preexposure prophylaxis for HIV infection: healthcare providers' knowledge, perception, and willingness to adopt future implementation in the southern US. South Med J. 2012;105:199-206
25. Van der Straten A, Van Damme L, Haberer JE, et al. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS. 2012;26:13-19
26. Hurt CB, Eron JJ, Cohen MS. Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost?. Clin Infect Dis. 2011;53:1265-1270
27. Golub SA, Kowalczyk W, Weinberger CL, et al. Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr. 2010;54:548-555
28. Guidance on Pre-Exposure Oral Prophylaxis (PrEP) for Serodiscordant Couples, Men and Transgender Women Who Have Sex With Men at High Risk of HIV: Recommendations for Use in the Context of Demonstration Projects. World Health Organization. Available at: http://www.who.int/.hiv/pub/guidance-prep/en/. Accessed February 1, 2014
29. Warren MJ, Bass ES. From efficacy to impact: an advocate's agenda for HIV pre-exposure prophylaxis implementation. Am J Prev Med. 2013;44 (1 suppl 2):S167-S170
30. HIV/AIDS Epidemiology Annual Report 2012. San Francisco Department of Public Health. Available at: http://www.sfdph.org/dph/files/reports/.RptsHIVAIDS/AnnualReport2012.pdf. Accessed July 2, 2014
31. Centers for Disease Control and Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP) Atlas. Available at: http://www.cdc.gov/nchhstp/atlas. Accessed July 2, 2014
32. Pilcher CD, Fiscus SA, Nguyen TQ, et al. Detection of acute infections during HIV testing in North Carolina. N Engl JMed. 2005;352:1873-1883
33. Napper LE, Fisher DG, Reynolds GL. Development of the perceived risk of HIV scale. AIDS Behav. 2012;16:1075-1083
34. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159:702-706
35. Rawlings K, Mera R, Pechonkina A, et al, eds. Status of Truvada (TVD) for HIV Pre-exposure Prophylaxis (PrEP) in the United States: An Early Drug Utilization Analysis. Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 10-13, 2013; Denver, CO
36. Glazek C. Why is no one on the first treatment to prevent HIV?. The New Yorker. September 30, 2013
37. Tuller DA. Resisted Pill to prevent HIV. The New York Times. December 30, 2013:Health
38. Liu A, Kittredge P, Vittinghoff E, et al. Limited knowledge and use of HIV post- And pre-exposure prophylaxis among gay and bisexual men. J Acquir Immune Defic Syndr. 2008;47:241-247
39. Mimiaga MJ, Case P, Johnson CV, et al. Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. J Acquir Immune Defic Syndr. 2009;50:77-83
40. Young I, McDaid L. How acceptable are antiretrovirals for the prevention of sexually transmitted HIV?: a review of research on the acceptability of oral pre-exposure prophylaxis and treatment as prevention. AIDS Behav. 2014;18:195-216
41. Smith DK, Pals SL, Herbst JH, et al. Development of a clinical screening index predictive of incident HIV infection among men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2012;60:421-427
42. Celum C, Baeten JM, Hughes JP, et al. Integrated strategies for combination HIV prevention: principles and examples for men who have sex with men in the Americas and heterosexual African populations. J Acquir Immune Defic Syndr. 2013;63(suppl 2):S213-S220
43. Wheelock A, Eisingerich AB, Ananworanich J, et al. Are Thai MSM willing to take PrEP for HIV prevention?. An analysis of attitudes, preferences and acceptance. PLoS One. 2013;8:e54288
44. Buchbinder S, Glidden DV, Liu AY, et al. Who should be offered HIV pre-exposure prophylaxis (PrEP)?. A secondary analysis of a phase 3 PrEP efficacy trial in men who have sex with men and transgender women. Lancet Infect Dis. 2014;14:468-475
45. Bernstein KT, Marcus JL, Nieri G, et al. Rectal gonorrhea and chlamydia reinfection is associated with increased risk of HIV seroconversion. J Acquir Immune Defic Syndr. 2010;53:537-543
46. Pathela P, Braunstein SL, Blank S, et al. HIV incidence among men with and those without sexually transmitted rectal infections: estimates from matching against an HIV case registry. Clin Infect Dis. 2013;57:1203-1209
47. Pathela P. Population-based HIV incidence among men diagnosed with infectious syphilis, 2000-2011. Presented at: 20th International Society for Sexually Transmitted Disease Research (ISSTDR); July 14-17, 2013; Vienna, Austria
48. Baeten JM, Haberer JE, Liu AY, et al. Preexposure prophylaxis for HIV prevention: where have we been and where are we going?. J Acquir Immune Defic Syndr. 2013;63(suppl 2):S122-S129